The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 28 February 2006, www.theannals.com, DOI 10.1345/aph.1G456.
 The Annals of Pharmacotherapy: Vol. 40, No. 3, pp. 433-440. DOI 10.1345/aph.1G456
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemon, M. D
Right arrow Articles by Farver, D. K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemon, M. D
Right arrow Articles by Farver, D. K

FORMULARY FORUM

Sodium Oxybate for Cataplexy

Michael D Lemon, PharmD

Associate Professor of Clinical Pharmacy, College of Pharmacy, South Dakota State University; Veterans Affairs Black Hills Health Care System, Fort Meade, SD

Joe D Strain, PharmD

Assistant Professor of Clinical Pharmacy, College of Pharmacy, South Dakota State University; Rapid City Regional Hospital, Rapid City, SD

Debra K Farver, PharmD

Professor of Clinical Pharmacy, College of Pharmacy, South Dakota State University; South Dakota Human Services Center, Yankton, SD

Reprints: Dr. Lemon, VA Black Hills Health Care System, 113 Comanche Rd., Pharmacy Service, Fort Meade, SD 57741-1099, fax 605/347-7207, Michael.lemon{at}med.va.gov

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, precautions, dosing recommendations, and patient counseling of sodium oxybate for the treatment of cataplexy in patients with narcolepsy.

DATA SOURCES: OVID and PubMed databases were searched (1966–January 2006) using the key words sodium oxybate, gamma-hydroxybutyrate, narcolepsy, and cataplexy. Only English-language articles were selected.

STUDY SELECTION AND DATA EXTRACTION: All information on sodium oxybate related to narcolepsy and cataplexy was considered. Study selection included human trials evaluating safety and efficacy of sodium oxybate for the treatment of cataplexy.

DATA SYNTHESIS: Sodium oxybate is approved by the Food and Drug Administration for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. In placebo-controlled trials, sodium oxybate demonstrated efficacy in reducing the number of cataplexy attacks. The dosing regimen includes a split dose given at bedtime and 2.5–4 hours later due to its short elimination half-life. The drug is generally well tolerated, with headache, nausea, dizziness, pain, and somnolence being the most common adverse events.

CONCLUSIONS: Sodium oxybate is safe and effective for the treatment of cataplexy. Potential disadvantages include a multiple dosing regimen, abuse potential, cost, and a closed distribution system. Potential advantages demonstrated in clinical trials include significant decreases in the number of weekly cataplexy attacks, improvement in daytime sleepiness, and improvement in the Clinical Global Impression of Change score and nighttime awakenings. Overall, sodium oxybate provides a new option for the treatment of cataplexy.

Key Words: cataplexy, narcolepsy, sodium oxybate

Published Online, February 28, 2006. www.theannals.com, DOI 10.1345/aph.1G456

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-06-005-H01




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.